Archive | April, 2023

Global Roadshow Information and Preparation

13 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN)’s Redefining Early Stage Investment (RESI) conference stands out from the average partnering conference. LSN, from the start, wanted RESI to be a dedicated partnering-centric event.  RESI content is centered on startups and the information they need to succeed in their fundraising endeavors, comprising of investor and licensing partner panels and service provider workshops (see program guides below). There are two main parts to the equation, the 10,000+ early-stage capital investors and licensing partners in the LSN ecosystem, and the 10,000+ startups that are a fit for RESI. This includes those seeking up to 2M in seed funding, $2-10M series A funding, and $10M to 50M series B funding.

The LSN BD staff are not just selling RESI tickets or the LSN investor database but spend a lot of time assessing and making sure that RESI attendees are ready for a global fundraise and understand what it takes to go from the regional stage to the global arena. LSN really cares about the ROI for our clients. It is because of this challenge I have put a bunch of useful links and info that we send along to our RESI and Data leads so that they know what to expect when designing and launching a global roadshow.

At first glance, there are a lot of links/info, but we have found that startups who really want to understand what LSN and RESI are all about typically take the time to explore the subtlety and nuances of going from a regional to a global roadshow mindset.

  • Big4Bio Interview

Listen to the podcast from LSN’s CEO, Dennis Ford, about the journey and challenges life sciences entrepreneurs make when they set out to raise money, what investors care about, and what steps they can take to ensure their success best.

The most successful entrepreneurs are always the best storytellers. Finding a way to formulate your company’s unique story naturally and portraying this through multiple modalities, whether it be a 1-minute elevator pitch or a 12-slide pitch deck, is one of the most effective ways to get potential investors and partners on board with your value proposition. This video will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the players that will emerge along a deal chain, and language tools to refine your hook.

Launching a startup begins with commitment. Commitment to your startup initiative, your executive team, and your partners. Learn how to sustain this commitment by creating a proof of concept or prototype and create market traction initially, considerations to your corporate structure, simplifying finances in the beginning, and what tools to utilize. This video takes you through an honest look at best practices for launching a life science startup.

  • RESI Program Guide

Life Science Nation (LSN) has developed a curriculum on the fundamentals of launching a global partnering campaign. 3 different options are available for early-stage life science startups looking to improve their skill set in fundraising, business development, sales, and marketing.

Exhibiting at RESI – Connect with Top Life Science Startups

13 Apr

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Redefining Early Stage Investments (the RESI conference series) is a unique gathering. Several hundred startup companies representing cutting-edge technologies from across the verticals of the life sciences attend RESI to meet the huge turnout of investors and to learn about the services that will help them develop and grow their companies.

Visibility and brand recognition with companies that will be raising funds and initiating R&D, pre-clinical, and clinical activities soon is key to add to the leads funnel. RESI gives service providers the chance to have an exhibit table right in the middle of all the activity, as well as a presence online, in our newsletter, and in the program guide.

In addition to meeting the startups, there is the opportunity to meet some of the hundreds of investors and licensing partners that have extensive portfolios of companies in need of crucial services.

For more information, reach out to the LSN Business Development Team!

Life Science Nation Business Development Team
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Cameron-Hurlburt
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Cameron Hurlburt
Manager of Business Development
Book a Meeting
Email Me

RESI-Boston-2023-June-1100px

Preparing for the Innovator’s Pitch Challenge (IPC) at RESI Boston

13 Apr

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

LSN is once again featuring The Innovator’s Pitch Challenge (IPC) at the upcoming in-person RESI Boston on June 5. The IPC has been immensely popular among life science entrepreneurs and startup founders that attend RESI. The selected finalists will be grouped into sector-themed pitch sessions, and each company will have 4 minutes to present and 8 minutes for Q&A with an investor panel. The IPC offers a unique opportunity for founders and CEOs to engage directly with a panel of seasoned investors, who are specialized in the sectors that they judge for, so that the feedback and questions can be highly practical and constructive for the participants. The IPC is not only popular among startups, it is also valued by many active investors as an efficient way to engage with startups within their sector of interest. Whether you are a startup CEO or an investor, we welcome you to participate in IPC at our upcoming conference.

With two months left until RESI Boston, LSN is organizing an online workshop to help participants prepare for the IPC, ensuring that they can leverage the opportunity to the fullest extent. Please see below for the workshop schedule, and don’t forget to submit your application for the IPC before April 21, the final deadline. We highly recommend you to apply as early as possible, so you will have more time to prepare and maximize your experience. I look forward to seeing you at our webinar next week.

FREE_WEBINAR_IPC_Apr-18-Banner

Hot Investor Mandate: Asia-Based Evergreen Fund Invests in Early Clinical Stage Biotech and Medtech, Investing Up to $10M in Companies in Sizable Markets

13 Apr

An evergreen fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The firm is most interested in companies addressing North Asia, USA, Europe, and LATAM markets.

The firm will invest in therapeutics, medical devices, diagnostics, and digital health products. In therapeutics, the firm is currently most interested in cell and gene therapy, nucleic acid drugs, and all novel drug delivery products. The firm prefers to invest from early clinical stage (Phase I) and beyond. In medical devices, the firm is opportunistic and is open to all types of technologies. In diagnostics, the firm is primarily interested in IVD and diagnostics tools. The firm prefers to invest in products that have entered clinical testing, and is open to investing in both 510k and PMA devices. Lastly, in digital health, the firm is open to all types of technologies including those that leverage AI. In terms of indications, the firm is most interested in chronic disease therapy / care, neuron disorders, and oncology.

The firm is looking for competent, experienced, and reliable management teams when considering investment. The fund typically requires a board seat in the companies it invests in.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm & Venture Builder Actively Seeks Therapeutics Opportunities, Investing From as Early as Discovery Phase

13 Apr

An investor and venture builder based in the US invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC’s Inaugural Fund Invests in Therapeutics, Diagnostics, and Life Science Tools, Can Also Invest in Likeminded Funds

13 Apr

An emerging venture fund is currently for their first fund and will invest from seed to early stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $0.5-3 Million, and may participate as a fund of funds. The firm is focused on investments in Southern California, but can invest in companies nationwide.

Within therapeutics, the firm is interested in small molecules, biologics, RNA platforms, and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases.

The firm is willing to lead or co-invest, is an active investor, and will request board participation after an  investment in helping the entrepreneur and company improve their chances for seeking subsequent financings and building value.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Supports Life Science Technologies Through Funding and Company Formation, Focusing on North America-Based Companies

13 Apr

A venture capital investment firm has a unique model that takes early-stage pre-company technologies and supports them in company formation. The firm invests in early stage pre-proof-of-concept companies that may have a longer development timeline. The firm provides investment and – dependent on the company – advisory roles to support the company to its next step in development. The firm typically invests around $250,000 per company, and currently manages a low to mid-million dollar fund, though has access to a greater market flow. The firm currently holds a portfolio of 11-12 deals, and is seeking to add 6-7 deals in their pipeline. The firm leads investments for small early stage companies, and co-invests into deals that are greater than $500K. Even while making seed investments, the firm has the ability to syndicate deals and provide value with an advisory role. The firm focuses on companies based in North America (USA & Canada), and has previously made investments in Texas, Ohio, North and South Carolina, Florida, and Canada, among others.

The firm currently has 4 clusters of companies, each separated by the following categories: pet health; hospital channeled products (hospital supply); rehabilitation and mobility; and hospital acquired infection sterilization. While the firm is constantly finding technology in these four clusters, The firm is open to look at all life science technologies outside of these clusters, including biotech therapeutics (especially biologics and regenerative medicine), medical devices, and diagnostics. For medical devices, the firm looks mainly at 510K consumer products (included plastic surgery), and would only invest in PMA devices under the right circumstances as a minor player/syndicate. The firm typically invests in products in the pre-clinical, in-development stage when the product is still an idea.

The firm prefers an experienced team in the space, and will help handpick the management team around the deal. The firm typically takes a board seat after an investment, especially as the first ones in for seed stage companies. The firm will likely invest in products with no IP or prototype, and will put the firm’s network of engineers to support the product and work with the IP.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →